Easier New Drug Development... SK Inc. C&C Expands Application Scope of 'iClue TDMD'

[Asia Economy Reporter Kang Nahum] SK Inc. C&C announced on the 6th that it will expand the application scope of 'iClue-Target Discovery for Metabolic Disease (iClue-TDMD),' jointly developed and launched with Gachon University Gil Medical Center.

iClue-TDMD is a service that discovers and verifies genes and proteins causing diseases using artificial intelligence (AI). By entering the name of the disease of interest or targets (factors causing the disease) into the search bar, it provides a list of targets with a high likelihood of success in new drug development along with analysis results.

Since its launch in February, it has provided specialized services for metabolic diseases such as obesity and diabetes, which have attracted significant interest in the global new drug research field.

The biggest change in iClue-TDMD is the support for new drug development for non-alcoholic fatty liver disease (NAFLD) through AI-based literature analysis. NAFLD is a metabolic disease with increasing incidence recently but still lacks clear treatments, making it a disease of high interest to pharmaceutical companies.

By reflecting the latest research paper data as well as omics data analysis results independently secured by Gachon University Gil Medical Center, the target analysis service has been expanded beyond diabetes and obesity to include the field of non-alcoholic fatty liver disease.

Omics refers to the academic field that helps handle all biological data sets related to genomics, transcriptomics, proteomics, metabolomics, etc., which are individually studied.

Additionally, by linking major domestic and international research papers and experimental data, the scope of searchable diseases has been expanded to all diseases. It provides correlation analysis results for targets based on five criteria: ▲Gene signaling pathways (Pathway) ▲Gene expression information (Expression) ▲Competitive drug development trends (Competition) ▲Research literature information (Literature) ▲Safety and side effects (Adverse Effects).

For researcher convenience, big data-based analysis and search functions have also been improved. The time-consuming process of searching and analyzing papers during target discovery research has been significantly shortened. Without separate searches, it shows the top-ranked target information frequently mentioned in recent papers, automatically provides information on the association between the selected target and disease, and enhances the paper analysis function.

Detailed condition searches have been subdivided so that researchers can filter targets easily with various scenarios.

Yoon Dongjun, head of SK C&C Healthcare Group, said, "iClue-TDMD quickly analyzes vast information, and the reliability of AI-derived target validity verification is high, which has received strong responses from researchers. We will continue to develop the service by reflecting researchers' demands."

This content was produced with the assistance of AI translation services.